-
Media ReleaseNovartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer
-
Media ReleaseNovartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis
-
Media ReleaseFDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year
-
Media ReleaseNovartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
-
Media ReleaseNovartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
-
Media ReleaseNovartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
-
Media ReleaseNew Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer
-
Media ReleaseNovartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)
-
Media ReleaseFDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
-
Media ReleaseNovartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
-
Media ReleaseNovartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
-
Media ReleaseNovartis launches "Meet The PROS" to raise awareness and support education for PIK3CA-Related Overgrowth Spectrum (PROS)